Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Brain Behav Immun. 2021 Jan 7;93:80–95. doi: 10.1016/j.bbi.2020.12.016

Figure 4. Systemic administration of the TLR2/TLR4 antagonist (+)-Naltrexone [(+)-NTX] beginning 14 days after intradermal myelin oligodendrocyte glycoprotein (MOG), reverses EAE-related pain and provides overnight pain relief in male Dark Agouti rats.

Figure 4.

Male Dark Agouti rats were baselined (BL) for low-threshold mechanical withdrawal thresholds via the von Frey test, followed by intra-dermal low-dose (4-µg) myelin oligodendrocyte glycoprotein (MOG). Allodynia was assessed thereafter across the timecourse shown. (+)-NTX (6 mg/kg subcutaneously [SC] 3x/day) vs. saline was initiated on Day 14 post-MOG, continuing through day 28 (see gray rectangle indicating span of drug delivery). Panels A and B: (+)-NTX reversed allodynia, relative to saline control (main effect of drug: left paw: F(1,6) =431.5, p<0.0001; right paw: F(1,6) =173.4, p<0.0001). Notably, withdrawal thresholds measured prior to each day’s initiation of (+)-NTX dosing on days 17, 23 and 28 (17-pre, 23-pre, 28-pre) were comparable to withdrawal measures post-(+)-NTX on those same days supportive of overnight pain suppression.